Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C. Walter T, et al. Among authors: ferru a. Dig Liver Dis. 2018 Feb;50(2):195-198. doi: 10.1016/j.dld.2017.11.020. Epub 2017 Dec 6. Dig Liver Dis. 2018. PMID: 29258812 Clinical Trial.
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM. Bourgeois H, et al. Among authors: ferru a. Am J Clin Oncol. 2006 Jun;29(3):267-75. doi: 10.1097/01.coc.0000217552.69036.16. Am J Clin Oncol. 2006. PMID: 16755180 Clinical Trial.
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D; SAMCO-PRODIGE 54 Investigators. Taïeb J, et al. JAMA Oncol. 2023 Oct 1;9(10):1356-1363. doi: 10.1001/jamaoncol.2023.2761. JAMA Oncol. 2023. PMID: 37535388 Free PMC article.
Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer.
Chautard R, Caulet M, Bouché O, Borg C, Manfredi S, Capitain O, Spano JP, Raoul W, Guéguinou M, Herault O, Ferru A, Pobel C, Sire O, Lecomte T. Chautard R, et al. Among authors: ferru a. Dig Liver Dis. 2024 Aug 19:S1590-8658(24)00886-7. doi: 10.1016/j.dld.2024.07.022. Online ahead of print. Dig Liver Dis. 2024. PMID: 39164167 Free article.
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.
Planchard D, Bourgeois H, Adoun M, Paitel JF, Blanc P, Genet D, Ferru A, Meurice JC, Deletage C, Tourani JM. Planchard D, et al. Among authors: ferru a. Am J Clin Oncol. 2006 Aug;29(4):345-51. doi: 10.1097/01.coc.0000221320.81753.a9. Am J Clin Oncol. 2006. PMID: 16891860 Clinical Trial.
Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.
Tougeron D, Sickersen G, Mouillet G, Zaanan A, Trouilloud I, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Lecomte T; Association des Gastro-Entérologues Oncologues (AGEO). Tougeron D, et al. Among authors: ferru a. Eur J Cancer. 2015 May;51(8):925-34. doi: 10.1016/j.ejca.2015.03.011. Epub 2015 Apr 8. Eur J Cancer. 2015. PMID: 25864037
Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.
Tranquart F, Dujardin PA, Bouché O, Marcus C, Borg C, Manzoni P, Douillard JY, Labbe-Devilliers C, Terrebonne E, Smith D, Trillaud H, Capitain O, Aubé C, Spano JP, Lucidarme O, Ferru A, Tasu JP, Manfredi S, Bleuzen A, Léger J, Lecomte T. Tranquart F, et al. Among authors: ferru a. Ultraschall Med. 2018 Oct;39(5):544-558. doi: 10.1055/s-0043-122497. Epub 2017 Dec 12. Ultraschall Med. 2018. PMID: 29232725 English.
35 results